# Cytokinetics Inc. (CYTK) — Stock CV

Cytokinetics Inc. is a $8.75B healthcare company. Revenue shrank 21.1% over the last year, it currently loses money, and it holds more cash than debt.

> Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

## Identity

- **Ticker**: CYTK
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: SOUTH SAN FRANCISCO, CA
- **Employees**: 673
- **Website**: https://www.cytokinetics.com
- **Market cap**: $8.75B
- **Last price**: $62.91
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $67.7M
- **Net income**: -$894M
- **Free cash flow**: -$581M
- **Net cash**: $636M
- **Revenue growth (YoY)**: -21.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 10 |
| Growth | 12 |
| Profitability | 0 |
| Health | 50 |
| Quality | 11 |
| Moat | 0 |

## Qualifications (beginner checklist) — 3 of 9 passed

- [ ] Revenue growing — -21.1% YoY
- [ ] Profitable — -$894M TTM
- [ ] Profit growing — -33.2% YoY
- [ ] Generates cash — -$581M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $8.75B market cap
- [x] Not printing shares — -99.7% shares over ~5y
- [ ] Proven track record — 1/10 profitable years
- [ ] Financially stable — health score 25/100

## Experience (career milestones)

- **FY2024** — Became debt-free: cash now exceeds total debt
- **FY2016** — First recorded profitable year: $16.5M net income
- **FY2016** — Best year on record: $16.5M net income
- **2006** — Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times
- **2004** — The company completed its initial public offering (IPO)
- **1997** — Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B

## Strengths

- Net cash position after subtracting debt from cash

## Watch-outs

- Revenue shrinking 21.1% year over year
- Not profitable — 1321.3% net margin
- Negative free cash flow (-$580.7M)
- Thin interest coverage (-14.3×)
- Loss-making in 9 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $70.4M | -$215M | -$191M |
| FY2022 | $94.6M | -$389M | -$311M |
| FY2023 | $7.53M | -$526M | -$416M |
| FY2024 | $18.5M | -$590M | -$400M |
| FY2025 | $88.0M | -$785M | -$535M |

---

Source: https://stockcv.com/CYTK — derived from company filings; may be delayed or incomplete. Information, not investment advice.